Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 009 JPY -0.79% Market Closed
Market Cap: 30.8B JPY
Have any thoughts about
Daito Pharmaceutical Co Ltd?
Write Note

Daito Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Daito Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Daito Pharmaceutical Co Ltd
TSE:4577
Additional Paid In Capital
ÂĄ7.1B
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
5%
Takeda Pharmaceutical Co Ltd
TSE:4502
Additional Paid In Capital
ÂĄ1.7T
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
41%
Daiichi Sankyo Co Ltd
TSE:4568
Additional Paid In Capital
ÂĄ4B
CAGR 3-Years
N/A
CAGR 5-Years
-47%
CAGR 10-Years
-28%
Otsuka Holdings Co Ltd
TSE:4578
Additional Paid In Capital
ÂĄ504.5B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Chugai Pharmaceutical Co Ltd
TSE:4519
Additional Paid In Capital
ÂĄ69.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
Astellas Pharma Inc
TSE:4503
Additional Paid In Capital
ÂĄ183.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
No Stocks Found

Daito Pharmaceutical Co Ltd
Glance View

Market Cap
30.7B JPY
Industry
Pharmaceuticals

Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Intrinsic Value
2 429.67 JPY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Daito Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
7.1B JPY

Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 7.1B JPY.

What is Daito Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
5%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Daito Pharmaceutical Co Ltd have been 5% over the past three years , 11% over the past five years , and 5% over the past ten years .

Back to Top